Drug Trial Radar · NCT04770779
A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)
Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
258
Actual
Start
Nov 30, 2021
Primary completion
Apr 11, 2024
Study completion Jun 2029
Sponsor
- Lead sponsor
- Agios Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 25, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study was to compare the effect of mitapivat versus placebo on transfusion burden in participants with α- or β-transfusion-dependent thalassemia.
Conditions
- Transfusion-dependent Alpha-Thalassemia
- Transfusion-dependent Beta-Thalassemia
Interventions
Placebo Matching MitapivatDrug
Tablets
MitapivatDrug
Tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Double-blind Period: Percentage of Participants Who Achieved Transfusion Reduction Response (TRR)Time frame: Double-blind Period: Baseline through Week 48
Locations
75 sites in 19 countries. Site status is shown where the registry gives one.
Phoenix Children's Hospital
Phoenix, Arizona
San Diego Hospital, UC San Diego Health
La Jolla, California
Children's Hospital Oakland
Oakland, California
Stanford Medicine
Palo Alto, California
Boston Children's Hospital
Boston, Massachusetts
Children's Hospital of Michigan
Detroit, Michigan
Weill Cornell Medical Center
New York, New York
Duke University Medical Center
Durham, North Carolina
Penn Medicine - University of Pennsylvania Health System
Philadelphia, Pennsylvania
Seattle Cancer Care Alliance, University of Washington
Seattle, Washington
Hospital Das Clínicas da Faculdade de Medicina de Ribeirão Preto - USP
Ribeirão Preto, Brazil
GSH Banco de Sangue de São Paulo
São Paulo, Brazil
MHAT "Dr. Nikola Vasiliev" AD
Kyustendil, Bulgaria
UMHAT "Dr. Georgi Stranski" Pleven
Pleven, Bulgaria
UMHAT "Sveti Georgi" EAD
Plovdiv, Bulgaria
SHATHD Sofia
Sofia, Bulgaria
UMHAT "Prof. Dr. Stoyan Kirkovich"
Stara Zagora, Bulgaria
Foothills Medical Centre
Calgary, Alberta, Canada
Toronto General Hospital, University Health Network
Toronto, Ontario, Canada
Rigshospitalet
Hovedstaden, Denmark
CHU Hôpital Henri Mondor
Créteil, France
Hôpital Edouard Herriot, CHU de Lyon
Lyon, France
CHU Hôpital de la Timone
Marseille, France
Hôpital Necker Enfants Malades
Paris, France
Charité - UB - CVK - Medizinische Klinik
Berlin, Germany
Universitätsklinikum Essen
Essen, Germany
Universitätsklinikum Leipzig
Leipzig, Germany
University General Hospital of Patras
Achaia, Greece
Laiko General Hospital
Athens, Greece
Children's Hospital Agia Sophia, National and Kapodistrian University of Athens Medical School
Athens, Greece
University Hospital of Ioannina
Ioannina, Greece
Ippokrateio General Hospital
Thessaloniki, Greece
Ospedale "A. Perrino" - Brindisi
Brindisi, Italy
Ospedale Pediatrico Microcitemico
Cagliari, Italy
Ospedale Sant'Anna
Ferrara, Italy
Ente Ospedaliero Ospedali Galliera
Genova, Italy
Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
Milan, Italy
A.O.U Di Modena
Modena, Italy
AOU L. Vanvitelli Universita degli Studi della Campania Luigi Vanvitelli
Naples, Italy
A.O.U. San Luigi Gonzaga
Orbassano, Italy
Showing 40 of 75 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.